Neurontin and its new more powerful version, Lyrica, are widely used for unapproved indications that are a flagrant danger to the public. These highly successful drugs were approved for use even though the FDA had no idea what they were really doing in the brain. A surprising new study shows that they block the formation of new brain synapses1, drastically reducing the rejuvenating potential of brain plasticity, which means that these drugs will cause brain decline faster than any substance known to mankind.
The problem of these drugs is compounded by their flagrant illegal marketing. Neurontin was approved by the FDA for epilepsy in 1994. The drug underwent a massive promotion not indicated on the label that cost Warner-Lambert $ 430 million (the first major fine for non-registered promotion). The medication is now owned by Pfizer. Pfizer also has Lyrica, a super powerful version of Neurontin. It has been approved by the FDA for various types of pain and fibromyalgia. Lyrica is one of four drugs that a subsidiary of Pfizer illegally traded, resulting in a $ 2.3 billion deal against Pfizer.
Although the marketing of these drugs has been heavily penalized, they continue to accumulate billions in sales of non-approved uses. Doctors use them for all kinds of nervous problems because they are good at suppressing symptoms. However, such uses can no longer be justified because the actual mechanism of the drugs is finally understood and they are creating a significant long-term reduction in nerve health.
The researchers in the previous study try to downplay the serious nature of drugs by saying that “adult neurons do not form many new synapses.” That simply is not true. The new science is showing that brain health during aging depends on the formation of new synapses. Even these researchers managed to question the common use of these drugs in pregnant women. How is a fetus supposed to produce new nerve cells when the mother takes a drug that blocks them?
These are the kind of situations in which the FDA should have ended. As usual, the FDA is sitting reflecting on a suicidal warning for Lyrica, while its unapproved uses include bipolar disorder and migraines. It is likely that the FDA will mix their thumbs during the next decade on the subject of brain damage. Be careful with consumers
Neurontin and Lyrica are highly toxic to the new brain synapses Çagla Eroglu, Nicola J. Allen, Michael W. Susman, Nancy A. O’Rourke, Chan Young Park, Engin Özkan, Chandrani Chakraborty, Sara B. Mulinyawe, Douglas S. Annis , Andrew D. Huberman, Eric M. Green, Jack Lawler, Ricardo Dolmetsch, K. Christopher Garcia, Stephen